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PENGESANAN ANTIGEN YANG DIKENALPASTI OLEH ANTIBODI 
MONOKLON IBMR3 PADA SEL LIMFOSIT DAN TITISAN SEL 
ABSTRAK 
Antibodi monoklon menunjukkan kegunaan yang tinggi dalam penyelidikan 
dan klinikal. Antibodi monoklon IBMR3 (IBMR3 MAb) telah menunjukkan 
keupayaan mengcam molekul yang mungkin berhubungkait dengan kompleks 
reseptor interleukin-4 (IL-4R). Selama ini, IL-4R sering dikaitkan dengan kanser. 
Tujuan penyelidikan ini adalah untuk mengesan pengekspresan antigen IBMR3 
(IBMR3 Ag)  pada sel mononuklear darah periferal (PBMC) dan panel titisan sel. 
Kaedah pewarnaan imuno menunjukkan IBMR3 MAb boleh mengcam antigen pada 
beberapa jenis sel termasuk sel epithelial, fibroblas, haematopoitik, kanser dan 
normal. Yang menariknya, IBMR3 Ag diekpres dengan signifikan dalam ruang 
sitoplasma tetapi tidak diekspres pada permukaan sel kecuali pada sel limfosit 
normal. Analisis pengekspresan IBMR3 Ag menunjukkan pengekspresannya adalah 
tinggi pada limfosit teraktif berbanding limfosit tidak teraktif tanpa mengambilkira 
jenis ejen mitogenik yang digunakan. Limfosit yang diaktifkan oleh CD3 MAb 
menunjukkan pengekspresan tertinggi (60.00 ± 1.94%) diikuti oleh limfosit yang 
diaktifkan oleh rangsangan PHA (41.23 ± 0.63%). Namun begitu, kombinasi 
rangsangan PHA dan IL-4 (38.78 ± 4.82%) menunjukkan pengekspresan yang 
hampir sama dengan pengekspren akibat rangsangan PHA sahaja (41.23 ± 0.63%). 
Rangsangan oleh IL-4 sahaja (22.51 ± 1.00%) dan PWM (22.00 ± 1.00%) sahaja 
menunjukkan pengekspresan pada kadar yang hampir sama dengan kawalan tanpa 
rangsangan (20.61 ± 0.88%). Asai MTS telah digunakan untuk menyiasat kesan 
inkubasi IBMR3 MAb dengan kultur PBMC dan sel Jurkat. Berdasarkan kepada 
xvii 
keputusan, proliferasi PBMC telah terencat sebanyak 10.00 ± 5.30% dan 6.60 ± 
5.10% pada tempoh inkubasi masing-masing selama 48 dan 72 jam. Sebaliknya, 
apabila IBMR3 MAb diinkubasi dengan sel Jurkat rangsangan proliferasi yang ketara 
diperoleh sehingga 57.90 ± 14.40% selepas 48 jam inkubasi. Namun, inkubasi lebih 
lama pada 72 jam menunjukkan penurunan proliferasi sebanyak 16.42 ± 12.70% 
berbanding kawalan. Analisis spektrometri jisim pada sel Jurkat menemukan lapan 
calon protin bagi molekul IBMR3, yang mana tujuh daripadanya adalah molekul 
yang selalu dihubungkaitkan dengan kanser. Salah satu protein dengan skor 
signifikan yang tinggi adalah YWHAZ. Pengekspresan melampau YWHAZ sering 
dikaitkan dengan kesan malignan pada banyak jenis kanser. Tambahan pula, subsrat 
bagi YWHAZ adalah protin yang diketahui terlibat dalam tapakjalan isyarat 
proliferasi IL-4. Oleh itu, IBMR3 Ag adalah berkemungkinan molekul yang 
mengambil bahagian dalam proses pembentukan tumor melalui penglibatannya 
dalam proliferasi sel. 
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IDENTIFICATION OF ANTIGENS RECOGNIZED BY THE 
MONOCLONAL ANTIBODY, IBMR3 ON LYMPHOCYTES AND 
ESTABLISHED CELL LINES 
ABSTRACT 
Monoclonal antibodies  have demonstrated significant utilities in both 
research and clinical applications. IBMR3 monoclonal antibody (IBMR3 MAb) has 
been shown to recognize a molecule that may be associated with the human 
interleukin-4 receptor (IL-4R) complex. IL-4 has been  shown to be extensively 
associated with cancer. The aim of this study is to identify the IBMR3 antigen 
(IBMR3 Ag) expressed in normal peripheral blood mononuclear cells (PBMC) and 
in a panel of established cell lines. Immunostaining revealed that IBMR3 MAb can 
recognize antigen in a variety of cell types, including epithelial, fibroblast, 
haemopoietic, cancer, and normal cells. Interestingly, IBMR3 Ag was found to be 
expressed in the cytoplasm but was absent on the cell surface except for normal 
lymphocytes. The analysis of IBMR3 Ag expression on lymphocytes showed that 
IBMR3 Ag expression was higher on activated lymphocytes compared to resting 
lymphocytes regardless of the type of mitogenic agents used. The lymphocytes 
activated by CD3 MAb demonstrated the highest expression (60.00 ± 1.94%) 
followed by those activated only by phytohaematoglutinin (PHA) stimulation (41.23 
± 0.63%). However, the combination of PHA with interleukin 4 (IL-4) stimulation 
(38.78 ± 4.82%) exhibited almost the same expression as PHA alone (41.23 ± 
0.63%). Stimulation by IL-4 alone (22.51 ± 1.00%) and pokeweed (PWM) alone 
(22.00 ± 1.00%) produced almost the same level of expression as unstimulated 
control (20.61 ± 0.88%). MTS assay was used to investigate the effect of IBMR3 
xix 
MAb incubation in PBMC and Jurkat cultures. According to the results, the PBMC 
proliferation was slightly inhibited by 10.00 ± 5.30% and 6.60 ± 5.10% at 48 and 72 
hours of incubation time, respectively. Conversely, when IBMR3 MAb was 
incubated with Jurkat cells, significant proliferation stimulation was observed and 
reached up to 57.90 ± 14.40% after 48 hours of incubation. However, longer culture 
incubation at 72 hours decreased culture proliferation by 16.42 ± 12.70% compared 
with control. Mass spectrometry on Jurkat cells revealed eight candidate proteins for 
IBMR3 Ag , seven of which are common molecules associated with cancer. One of 
the proteins with high significance score was YWHAZ. Overexpressed YWHAZ has 
been correlated with malignant outcomes of several cancers. Moreover, the substrate 
for YWHAZ binding is known to be a protein involved in the IL-4 proliferation 
signaling pathway. Therefore, IBMR3 Ag could be a molecule that participates in 
tumorigenesis through involvement in cell proliferation.  
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CHAPTER 1  
 
INTRODUCTION 
1.1 Background of the study 
Monoclonal antibody (MAb) is a biomolecule that is widely used in research and 
clinical applications. Antibody–antigen binding, which was envisioned as the “magic 
bullet” concept by Paul Ehrlich over 100 years ago, is a potentially important basis in 
developing monoclonal antibodies as potential alternative for unspecific chemical 
anticancer agents. Treatment with antibodies, which are naturally occurring in the 
human body, is expected to produce fewer side effects compared to chemical or 
radioactive agents (Hansel et al., 2010). However, the method to achieve optimal 
delivery to the target tissue remains unknown (Coulson et al., 2014). Through 
hybridoma technology, which was first developed by Kohler and Milstein in 1975, a 
monoclonal antibody can be generated against anything that initiates antibody 
production (Kohler and Milstein, 1975). Thus, any type of antibody can be potentially 
created. Antibodies are common and essential tools for many research applications, 
including Western blot analysis, immunohistochemistry, immunocytochemistry, 
enzyme-linked immunosorbant assay (ELISA), immunoprecipitation, and flow 
cytometric analysis. In clinical applications, antibodies are used in managing many 
diseases, including cancer. At present, monoclonal antibodies are progressively being 
developed for a larger spectrum of therapeutic applications as well as for cancer 
diagnosis, prognosis, therapy, surveillance, and monitoring devices.  
Cancer is a disease caused by the abnormal proliferation of cells. Pathologically, 
cancer is categorized as benign or malignant. A benign tumor remains locally in its 
original location, whereas a malignant tumor can invade surrounding tissues and spread 
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throughout the body of a host. The ability to invade and spread, which is referred as 
metastasis, makes cancer a fatal disease (Hanahan and Weinberg, 2000). Cancers are 
classified into several major groups, including carcinoma, sarcoma, and leukemia or 
lymphoma. Approximately 90% of human cancers are malignancies of epithelial cells 
known as carcinoma. Sarcomas, which are usually rare, are tumors of connective 
tissues, bones, cartilages, and fibrous tissues. Roughly 8% of human malignancies are 
identified as leukemia and lymphoma, which result from blood-forming cells and cells 
of the immune system, respectively (Cooper and Hausman, 2000). 
Interleukin 4 (IL-4) cytokine is one of the essential lymphocyte growth factors 
for fundamental cell functions (Luzina et al., 2012). The expression of IL-4 cytokine 
and its receptor in a number of cancer types are well-documented (Suzuki et al., 2015, 
Venmar and Fingleton, 2014). However, the role and involvement of cytokine and 
cytokine receptors in cancer remain controversial (Li et al., 2009a). Four synthetic 
peptides were used in a previous study to generate monoclonal antibodies against 
human IL-4 receptor (IL-4R) to characterize the role of the receptor in cancer 
progression or tumorigenesis (Mat, 1992b). These peptides correspond to selected 
sequences of human IL-4R amino acids from the cDNA sequence published in 1990 
(Galizzi et al., 1990). These peptides that represent the extracellular and intracellular 
domains of the IL-4R complex were chosen because of their potential immunogenicity. 
The amino acid sequences of the peptides are shown in Figure 1.1. The resulting MAb 
raised against commercially prepared synthetic peptides were expected to cross-react 
with the native human IL-4R protein. However among the generated MAbs, only 
IBMR3 was reactive against native and denatured antigens. In a preceding functional 
study, IBMR3 MAb did not significantly inhibit the IL-4 induced proliferation of 
peripheral blood lymphocytes. In the assay, IBMR3 was added simultaneously with 
3 
recombinant IL-4 to a lymphocyte culture (Mat, 1992a). However, a previous work 
determined that the preincubation of the  with IBMR3 MAb before adding IL-4 to the 
culture system inhibited the subsequent proliferative response of MO7 (IL-3 and IL-4 
dependent monocyte cell line) cells. These preliminary data demonstrated the possibility 
that IBMR3 MAb may recognize a part of the human IL-4 receptor complex at low 
affinity (Mat, 1992a). 
1MGWLCSGLLFPVSCLVLLRVASSGNMKVLQEPTCVSDYMSISTCEWKMNGP
TNCSTELRLLYQLVFLLSEAHTCVPENNGGAGCVCHLLMDDVVSADNYTLDL
WAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYN
HLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRWAQCYNT
TWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKKEWW
DQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHN
MKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVE
CEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQ
DMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSP
DNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVP
QLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGT
QASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGC
PGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQE
QATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCG
DRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSS
QTPKIVNFVSVGPTYMRVS 825 
Figure 1.1 Amino acid sequence of the human IL-4 receptor cDNA. The sequences 
that are used to synthesize peptides to raise IBMR3 are indicated in bold 
letters (MKVLQEPTCVSDY is peptide 5; SENDPADFRI is peptide 2; 
WSEWS is peptide 3; and FVSVGPTYMRVS is peptide 4) Adopted 
from (Mat, 1992a). 
1.2 Problem Statement 
A considerable number of publications reported that IL-4R was overexpressed in many 
cancer types, such as melanoma, breast carcinoma, and ovarian carcinoma. The level of 
IL-4 cytokine was correlated with malignant transformation (Li et al., 2005, Kawakami 
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et al., 2004, Kaklamanis et al., 1996). Furthermore, the upregulated expression of IL4-R 
was observed in glioma, breast, lung, colon, and many other types of malignancies 
(Joshi et al., 2014, Todaro et al., 2008, Prokopchuk et al., 2005, Murata et al., 1998). 
However, the role of IL-4R in cancer remains debatable. In vivo and in vitro studies 
indicated that IL-4 is a tumor growth-supporting cytokine in murine myeloma and colon 
cancer cell line (Li et al., 2009a, Li et al., 2008a). In contrast, IL-4 also inhibited the 
proliferation of human renal, breast, and colon cancer cells (Gooch et al., 2002, Okada 
et al., 2001). At present, continuous efforts are carried out to understand the function of 
IL-4R in cancer although IL-4 is considered as the most understood cytokine (Banderas 
et al, 2012; Koller et al., 2010). 
IBMR3 MAb was previously raised against the IL-4R peptide (Mat, 1992). The 
result of ELISA indicated that IBMR3 MAb binds to the peptide that it was raised 
against (Mat, 1992). ). However, IBMR3 MAb failed to inhibit the proliferation of cell 
culture when it was added with IL-4 cytokine . (Mat, 1992).. Thus IBMR3 MAb may 
bind to IL-4R associated molecule yet it was not clear what IBMR3 Ag is. Previous 
results showed that IBMR3 MAb recognized protein with different molecular weights 
between Jurkat and normal PBMC lysates (Abas et al., 2008). We hypothesized that 
IBMR3 Ag may play a role during transformation from normal to cancer cells. Hence, 
characterization and identification of IBMR3 Ag may help to understand the importance 
and involvement of the molecule in cancer , thus provide basis for possible application 
of IBMR3 MAb in cancer management. 
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1.3 Objectives of the Study 
1. To analyze IBMR3 antigen expression and localization on lymphocytes as well 
as on Jurkat, HT29, Hep2 and 3T3 cell lines. 
2. To examine the modulation of the IBMR3 antigen expression on mitogen-
activated versus resting normal lymphocytes and Jurkat cells. 
3. To determine IBMR3 MAb binding effect on normal PBMC and Jurkat  
proliferation. 
4. To identify the IBMR3 antigen in Jurkat cells. 
1.4 Literature review 
1.4.1 Antibody and its general characteristics 
Antibody is a group of glycoproteins also commonly known as immunoglobulins. 
Globulin is among the three types of human serum protein besides albumin and 
fibrinogen (Schroeder and Cavacini, 2010). The term globulin encompasses a 
heterogeneous group of proteins that typically have high molecular weight, and both its 
solubility and electrophoretic migration rates are lower than those of albumin. Among 
these proteins, gamma globulins were found to be immunologically active and were 
therefore later called immunoglobulins (Louise and Louise, 2009).  
In nature, antibodies can be found in body fluids, including blood plasma, tears, 
saliva, and colostrum. Immunoglobulin molecules have five distinct isotypes recognized 
in higher mammals: IgM, IgG, IgA, IgD, and IgE. These immunoglobulin types differ 
in characteristics, such as molecular weight, serum concentration, and carbohydrate 
component (Louise and Louise, 2009). The primary function of antibodies is to 
neutralize bacterial toxins or certain viruses following their binding with antigen. A 
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secondary interaction of antibodies with another effector agents is usually required to 
dispose larger antigens such as bacteria (Späth, 1999). 
1.4.2 Structure of a typical antibody molecule 
Most antibodies used in cancer diagnosis and therapy are derived from the IgG isotype. 
The IgG isotype antibody consists of two antigen-binding fragments (Fabs) connected 
through a flexible region (hinge) to a constant (Fc) region (Figure 1.2). This structure 
has two pairs of polypeptide chains, with each pair containing a heavy and a light chain 
of dissimilar sizes. Both heavy and light chains are folded into immunoglobulin 
domains. The variable domains in the amino-terminal part of the molecule are the 
domains that identify and bind antigens. The rest of the molecule is composed of 
constant domains that vary among immunoglobulin isotypes that give them unique 
properties and functions. The Fc portion of the immunoglobulin serves to bind a variety 
of effector molecules of the immune system aside from being associated with the serum 
half-life of antibodies (Schroeder and Cavacini, 2010, Trail et al., 2003).  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic structure of an immunoglobulin G (IgG). Adopted from  
(Hansel et al., 2010). 
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1.4.3 Monoclonal versus polyclonal antibodies 
The decision of whether to use a polyclonal antibody (PAb) or monoclonal antibody 
(MAb) depends on a number of factors. The most important factor is its intended use. 
The production of PAb is more rapid at several months, inexpensive, and requires less 
technical skill than that of MAb (Ritter, 2000). PAb consists of heterogeneous 
antibodies that bind to multiple epitopes. Thus, PAb is less sensitive than MAb to small 
changes in epitope structure due to genetic polymorphism, denaturation, or 
glycosylation. These antibodies are stable over a wide range of pH and salt 
concentrations (Lipman et al., 2005). PAb is particularly useful in applications that 
recognize more than one epitope (antibody binding site) on a target molecule or where 
the molecule of interest is highly conserved. The most common application of PAb is 
for the detection of multiple epitopes as secondary, conjugated reagents for indirect 
immunoassays. In the application, polyclonal binding to the primary layer antibody 
leads to considerable amplification of the signal detection (Pohanka, 2009). A major 
problem of PAb use is on its limited amount of production. A PAb can never be exactly 
reproduced as different animals cannot produce identical responses toward the same 
immunogen. For this reason, different batches of PAbs will have different ranges of 
specificities and affinities (Lipman et al., 2005).  
By contrast, the generation of MAb is time consuming, costly, and requires 
highly trained technical skill. The generation of MAb-producing cells, the hybridomas, 
can take up to a year or longer (Ritter, 2000). The main advantages of MAbs are their 
homogeneity and consistency. Once characterized, the behaviors of MAbs are 
predictable. Identical MAbs can be produced infinitely. The greatest effect of MAbs is 
their use for discovering and characterizing the structure and function of novel 
molecules. Nearly all molecules that are known to be important in immune response 
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were previously identified through the generation of specific MAbs. The homogeneity 
of MAb provides excellent specificity towards a single epitope (Lipman et al., 2005, 
Pohanka, 2009). However the same monospecificity also limits their utility as MAb 
functions are susceptible to slight changes in epitope structure. To date, MAbs have 
demonstrated success in broad applications, and humanized MAbs are now the fastest-
growing group of biotechnology-derived molecules in clinical trials (Nelson et al., 
2010). 
1.4.4 MAbs and their clinical applications 
MAbs are monospecific antibodies made by identical clones of plasma cells in contrast 
to PAbs, which are made from several different cell clones. Since the introduction of the 
revolutionary MAb technology by Kohler and Milstein in 1976, the continuous 
production of large amounts of single-type antibodies known as MAbs have been made 
possible (Köhler and Milstein, 1976). Many efforts to improve MAb treatment efficacy 
while decreasing toxicities have led to the development of a large variety of engineered 
MAbs for research, diagnosis, and therapy tools. In various categories, MAbs are used 
in their naked, conjugated, chemically-modified, fragmented, or genetically 
recombinant modified forms (Sapra and Shor, 2013). 
1.4.5 MAb production 
The production of MAbs is achieved using a couple of different techniques, one of 
which involves the formation of hybridoma cells. Hybridomas are generated by the 
fusion of immune spleenocytes with myeloma. The spleen cells are extracted from a 
mouse previously exposed to the antigen of interest. The resulting hybridoma when 
grown produces certain antibodies constitutively as an outcome of the antibody-
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producing spleen cells and rapidly growing immortal myeloma cells (McCullough and 
Spier, 1990, Kohler and Milstein, 1975). However, MAbs isolated from animal hosts, 
such as murine species, induce human anti-mouse antibody (HAMA) response in 
humans (Tjandra et al., 1990).  
To decrease immunogenicity, MAbs are commonly modified into chimeric or 
humanized constructs. Genetic engineering is used to fuse the antigen binding region 
(variable domains of the heavy and light chains, VH and VL) from murine-derived 
MAbs with the constant region from human sources (Figure 1.3). The chimeric MAbs 
successfully improved the efficacy and reduced the HAMA response of some 
therapeutic MAbs (Hwang and Foote, 2005). However, the perception of murine-
associated risk drove the MAb technology to the production of humanized MAbs 
(Reichert et al., 2005). These antibodies are constructed with only antigen-binding 
regions derived from a mouse and the remainder regions from a human source. Later, to 
circumvent the immunogenicity issue of murine-derived antibodies, fully human 
antibodies were generated in transgenic mice. With the advent of DNA recombinant 
technology, this production was achieved by replacing antibody genes in mice with 
human genes. Thus, fully human antibodies are produced by transgenic mice in 
response to immunization with a certain antigen (Hwang and Foote, 2005). Another 
method to produce these types of antibodies is by fusing antibody-encoding genes with 
a capsid protein of a bacteriophage. In addition to phage display antibodies, antibody 
fragments or full molecules can also be presented in yeast, bacteria, and mammalian 
cells (Deantonio et al., 2014, An, 2008). In the early stage of DNA recombinant 
technology in the 1980s, the generation of human hybridomas was derived from human 
lymphocytes and myeloma cell lines. Nonetheless, the approach was proved to be 
unreliable, produced insufficient antibody quantity, and was vulnerable to 
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contamination. Another limitation is that, “immunizing” patients in a controlled manner 
and then collecting the resultant lymphocytes was not allowed for ethical reasons 
(Nissim and Chernajovsky, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Modifications of MAbs. Adopted from (Kim et al., 2005). 
1.4.6 Categories of MAbs for therapeutic use 
Human antibody production by conventional hybridoma technology is difficult because 
the in vivo immunization of humans is not feasible for many antigens (Smith et al., 
2013). In addition, the conventional hybridoma technology does not produce stable 
levels of antibodies. About 75% of the currently available therapeutic antibodies are 
full-length IgG molecules (Reichert, 2012). One reason for this situation is that IgGs are 
structurally stable, have long in vivo half-life, and confer Fc-mediated biological 
properties. Nonetheless, being whole molecules with a molecular weight of about 150 
kDa, IgGs penetrate poorly from the vascular bed into a tumor tissue mass and clear 
slowly from the body (Chang et al., 2002). Aside from whole molecule antibodies 
(Zider and Drakeman, 2010), antibody fragments can also be generated into Fabs, 
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single-chain fragments, diabodies, minibodies, and others (Figure 1.4). Relative to 
whole molecules, these antibodies with smaller-sized fragments have better penetration 
and improved clearance characteristics (Chang et al., 2002). These characteristics make 
antibody fragments more suitable for imaging and radiotherapy. The lack of Fc region 
eliminates immunogenicity against Fc, and thus the therapeutic side effects may be 
reduced. Another advantage is that this construct can be produced at low costs. Even 
though these fragments have shorter plasma half-lives than whole antibodies, this 
setback can be compensated by PEGylation modification (Chapman, 2002).  
 
Figure 1.4 Recombinant antibodies for cancer therapy. Schematic diagram of the 
evolution of antibodies from murine (green shading) to humanized (blue 
shading) and various fusion proteins. Red spheres indicate glycosylation 
in the CH2 domain, pink shading indicate the VH/VL domains from one 
scFv, and yellow shading represents any fusion protein partner. bs: 
Bispecific; dAb: Single-domain antibody; ds: Disulphide; scFv: Single-
chain antibody fragment. Adopted from (Zider and Drakeman, 2010). 
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1.4.7 Clinical applications  
Various anti-hemagglutinin MAb approaches have become major targets for influenza 
research to neutralize the influenza virus (He et al., 2013b). Besides, MAbs against 
cluster of differentiation (CD) markers are extensively used to study many diseases, 
especially hematological malignancies. Examples include anti-CD34 and anti-CD44 
MAb, which are employed to study mesenchymal damage caused by chemotherapy for 
leukemia, myeloma, myelodysplasia, and lymphoma to identify treatment side effects 
(Kemp et al., 2010). 
 Recently, ELISA based on an MPT64 antibody has been found useful for the 
diagnosis of pulmonary tuberculosis in both sputum-smear-positive and -negative 
patients (Zhu et al., 2012). Serological markers, such as anti-Saccharomyces cerevisiae 
antibodies and perinuclear antineutrophil cytoplasmic antibodies, and the recently 
reported anti-glycan antibodies, anti-laminaribioside, anti-chitobioside, and anti-
mannobioside carbohydrate antibodies are widely utilized for the serological diagnosis 
and stratification of inflammatory bowel disease patients (Werner et al., 2013). MAbs 
are also used as diagnostic tools in supporting the diagnosis of specific forms of cancer, 
such as calretinin detection in mesothelioma (Chhieng et al., 2000).  
For therapeutic applications, MAbs have rapidly become a clinically important 
class of drug. In 2012, more than 26 antibodies were marketed in the United States and 
Europe, and more than 350 were under clinical evaluation worldwide. These antibodies 
are used for the treatment of a wide range of diseases, including organ transplantation, 
autoimmunity and inflammation, cancer, cardiovascular diseases, infectious diseases, 
and ophthalmological diseases (Reichert, 2012, Chan and Carter, 2010) .  
MAbs are also used as prognostic tools in treatment selection, e.g., anti-HER2 in 
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breast cancer and as the basis for targeted imaging studies, including anti-CEA- and 
anti-CAIX-based imaging (Pillay et al., 2011). In most cases, more than single 
antibodies are necessary to demonstrate sufficient sensitivity or specificity to be used 
for any indications mentioned above. 
1.4.8 MAbs for cancer treatment 
Conventional anticancer therapeutics remains important and widely used as treatment 
options for many types of cancers. However, the broad specificity results in toxicities, 
which usually limit the optimal dosing of anticancer drugs. Thus, suboptimal dosing 
eventually leads to relapse, drug resistance, and limited efficacy among cancer patients 
(Hackbarth et al., 2008, Gonzalez-Angulo et al., 2007, Kayl and Meyers, 2006). The 
challenge to find specific agents is selecting tumor cells over normal cells despite the 
fact that they share many common features. One possible strategy to overcome this is to 
harness the property of precision-guided MAbs to deliver the drugs to the tumor cells. 
Antibodies can exert an anti-tumor effect through four mechanisms, namely, 
perturbation of tumor cell signaling, activation of complement-dependent cytotoxicity 
(CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of adaptive 
immunity (Scott et al., 2012a), as described below. 
1.4.9 Mechanism of action of therapeutic antibodies for cancer treatment 
IgG2 and IgG4 are designed primarily for signaling perturbation, and they do not 
activate CDC (Shuptrine et al., 2012). Increased expressions of growth factor receptors 
during tumorigenesis make them an interesting target for therapeutic antibodies (Di 
Lorenzo et al., 2002). MAbs can exert antitumor effects by blocking ligand binding to 
growth factor receptors, thereby inhibiting proliferation, inducing apoptosis, or 
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sensitizing tumor to chemotherapeutic agent (Mendelsohn and Baselga, 2000). 
Cetuzimab and Panitumumab, which are currently approved for the treatment of cancers 
of the head and neck and colon, are reported to function by binding to the epidermal 
growth factor receptor (EGR) (Li et al., 2005). They prevent EGF binding, which 
activates tumor proliferation and neoangiogenesis, thus reducing cell proliferation and 
tumor angiogenesis. 
Both ADCC and CDC are mediated through the Fc region of antibodies, with 
the MAbs of the IgG1 isotype being the most effective at inducing ADCC and CDC 
(Natsume et al., 2009). CDC causes cell destruction through complement system 
activation. In CDC, the Fc portion activates the classical complement system following 
its interaction with C1q (component of the complement system), thus leading ultimately 
to the formation of a membrane-attack complex. Both IgG3 and IgG1 have been found 
to be essential for the interaction between IgG and C1q (Shuptrine et al., 2012). CDC 
was reported to contribute to the antitumor activity of the anti-CD20 rituxiMAb, a MAb 
used in the treatment of non-Hodgkin's lymphoma (Di Gaetano et al., 2003). Recently, 
Moore and co-workers (2010) described the generation of a series of Fc variants with 
improved ability to recruit complement. The variants generated enhanced the cytotoxic 
potency of the anti-CD20 monoclonal IgG1 antibody, OcrelizuMAb up to 23-fold 
against tumor cells in CDC assays, and they demonstrated a correlated increase in C1q 
binding affinity, thus improving the CDC activity (Moore et al., 2010).  
The Fc domain of antibodies can activate ADCC by interacting with the Fc 
receptors (FcγRs) in the effector immune cells. Natural killer (NK) cells that 
predominantly express FcγRIIIA are the main effectors of ADCC apart from 
macrophages and granulocytes, which have been shown to mediate ADCC to a lesser 
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extent (Stewart et al., 2014). Through the interaction between the FcγRs in the effector 
cells and the MAb Fc domain, NK cells release cytokines, such as interferon-γ (IFN-γ), 
and cytotoxic granules containing perforin and granzymes, which enter the target cell 
and promote cell death by triggering apoptosis (Nimmerjahn and Ravetch, 2007). The 
balance in the expression between activating and inhibitory FcγRs seems to be an 
important determinant of clinical efficacy because in vivo studies indicated that 
Trastuzumab and Rituxumab anti-tumor effects require functional activating FcγRs. 
Mice lacking the expression of FcγRIIIB exhibit a greater anti-tumor response after 
antibody treatment compared with mice with a deficient expression of activating 
FcγRIIIB (Clynes et al., 2000). 
Tumor antigens are processed by dendritic cells (DCs) through endocytic 
phagocytosis and are presented in the major histocompatibility complex class II (MHC 
II). The main function of the MHC II molecule is to present processed antigens, which 
are derived primarily from exogenous sources, to activate CD4+ T-lymphocytes. 
Likewise, DCs are capable of cross-presenting the phagocytozed tumor antigen in the 
MHCI molecule to generate tumor-specific CD8+ cytotoxic T cells (CTLs). Upon 
activation, CTLs kill tumor antigen-loaded on MHCI cells or further differentiate into 
specific memory cells. (Holling et al., 2004). This mechanism was suggested to 
contribute to the clinical efficacy of some antibodies. CTLs had been shown to be 
capable of killing primary ovarian and melanoma cells after being activated by DCs 
loaded with antibody-coated ovarian and melanoma cells (Cioca et al., 2006). In an in 
vitro study investigating cetuximab immune-mediated effects that contribute to the 
antibody anti-tumor effectiveness for colon cancer, DCs loaded with drug-treated 
cetuximab-coated colon cancer cells were used to generate CTLs. The consequent DC-
mediated cross-priming of antigens elicited a robust CTL anti-tumor response (Correale 
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et al., 2012). 
1.4.10 Types of MAb conjugates 
In addition to the development of naked or unconjugated MAb based on effector 
function and signaling inhibition, MAbs that attach to toxic agents are also being 
developed. The conjugation of MAb with radioisotopes, toxin, cytotoxic drugs, or 
liposomes can increase the specificity of the toxic agents, improve treatment efficacy, or 
reduce systemic toxicity (Trail, 2013). 
1.4.10(a) Immunotoxins 
Antibody–toxin conjugates, which are also called immunotoxins, are combinations of 
toxin molecules derived from plants, fungi, or bacteria that are chemically conjugated or 
genetically fused to an antibody or an antibody fragment specific to the antigen on the 
tumor surface (Trail, 2013). Natural whole toxin molecules usually possess cell-binding 
properties responsible for non-specific toxicity toward normal tissue (Romano et al., 
2007). Thus, first-generation immunotoxins have major limitations, including serious 
side effects and lack of specificity and immunogenicity. Redesigned versions of toxin 
units through protein truncation, mutation, and domain elimination were generated 
eventually (Becker and Benhar, 2012). For example, truncated versions of 
Pseudomonas aeruginosa exotoxin A (PE), including PE35, PE38, and P40, have been 
used for conjugation to antibodies. Similarly, truncated or mutated forms of diphtheria 
toxin (DT) were also generated. Both DT and PE exert their toxicity upon 
internalization inside the cells. Soon after the immunotoxin binds to the target molecule, 
PE-based immunotoxin undergoes receptor-mediated endocytosis (Słomińska-
Wojewódzka and Sandvig, 2013). In the endosome, the protease cleaves the 
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immunotoxin into two subunits. One of the subunits is further transported to the 
endoplasmic reticulum (ER) through the trans-Golgi network before reaching the 
cytosol. Finally, the catalytic ADP ribosylation of elongation factor II occurs, leading to 
apoptotic cell death (Słomińska-Wojewódzka and Sandvig, 2013). 
LMB-2 immunotoxin is composed of the murine anti-CD25 MAb linked to a 
scFv of PE38 (PE at 38 kDa size). In the interleukin-2 receptor (IL-2R) molecule, CD25 
is only expressed after T-cell activation but is not expressed in the resting lymphocytes 
(Chao et al., 2002). IL-2Rs have been greatly expressed in autoimmune diseases and 
various hematopoietic malignancies (Wilde et al., 2014, Houghton and Arceci, 2010). 
LMB-2 was the first recombinant immunotoxin that induced a major response in cancer. 
In one of the clinical trials, one patient with hairy cell leukemia achieved complete 
remission, whereas the remaining three patients achieved partial remission. Partial 
remissions were also observed in 1 patient with cutaneous T-cell lymphoma, 1 patient 
with chronic lymphocytic leukemia, and 9 patients with adult T-cell leukemia 
Hodgkin’s disease. Responding patients had 2–5 log reduction of circulating malignant 
cells, improvement in skin lesions, and regression of lymphomatous masses and 
splenomegaly (Kreitman et al., 2000). LMB-2 was evaluated in patients with metastatic 
melanoma as a combinatorial approach (with MART-1 and gp100-specific peptide 
vaccination), and the results showed a 79% reduction of circulating CD25+CD4+ T 
cells and 51.4% reduction of FOXP3+CD4+ T regulatory cells (Tregs) in patients’ 
peripheral blood (Powell et al., 2007). Tregs possess the ability to suppress T-cell 
responses and regulate tolerance to self-protein (Corthay, 2009).  
Although they showed promising results during pre-clinical evaluations, some 
PE-based immunotoxins, including OVB3-PE and ERB-38, failed to induce a favorable 
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response in patients. Indeed, hepatoxicity was observed in all five breast cancer patients 
and one esophageal cancer patient (Pai-Scherf et al., 1999, Pai et al., 1991). 
The early generation of a plant toxin, ricin A chain (RTA), demonstrated 
impressive pre-clinical results. The elimination of a cell-binding domain successfully 
avoided interference in the macrophages and in the endothelial system uptake. 
Moreover, deglycosylation of the RTA reduced the binding to the mannose receptor, 
thus resulting in a longer half-life in mice and a better therapeutic index (Ponder and 
Waring, 2012). The RTA-based immunotoxin enters the cell by endocytosis upon 
binding to the target molecule. The endosome unites with the Golgi system and then 
with the ER to deliver the immunotoxin. In the ER, the RTA is reduced through a 
disulfide bond cleavage into A and B chains (Becker and Benhar, 2012). From the ER, 
the A chain is translocated to the cytosol, where the RTA inactivates the ribosomes, 
eventually stops protein production in the cell, and causes cell death. The RTA-
conjugated antibodies against CD25 and CD30-positive Hodgkin’s lymphoma have also 
been exploited in clinical studies because of the high concentrations of lymphocyte 
activation markers, such as CD25 and CD30, being expressed in Hodgkin cells. The 
results demonstrated the partial remission of 2 out of 15 patients and 1 out of 17 patients 
for CD25 and CD30, respectively (Engert et al., 1997). The following clinical trial also 
showed a few patients responding probably because of the low number of CD30+ 
peripheral blood mononuclear cells and the binding of antiCD30 to soluble CD30 
antigen. However, RTA-based immunotoxin applications were usually compromised 
because of dose-limiting toxicities, including vascular leak syndrome, myalgia, hepatic 
damage, and immunogenicity (Słomińska-Wojewódzka and Sandvig, 2013). 
In fact, toxins of human origins are currently being developed to diminish the 
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immunogenicity or toxicity concerns of plants or bacterial immunotoxins. The toxins 
include pro-apoptotic proteins, RNAses, or kinases (Lorberboum-Galski, 2011). Human 
RNAses can induce the apoptosis of cancer cells. The internalization and effective entry 
into the cytoplasm of RNases degrade RNAs, thus causing p53-independent apoptosis 
(Lorenzo and D'Alessio, 2008). 
1.4.10(b) Antibody drug conjugates 
An antibody drug conjugate (ADC) consists of a MAb chemically coupled to a linker 
and a cytotoxic drug. Initially, ADC constitutes internalizing and non-internalizing 
MAb, following binding to target antigens. Non-internalizing ADC utilizes linkers 
designed to be cleaved or hydrolyzed by enzymes, such as cathepsin, matrix 
metalloproteinases, or acidic pH, present at the tumor site. Unlike non-internalizing 
ADC, the internalizing ADC delivers cytotoxic drugs more effectively when the 
metabolic potential of the endosomes and lysosomes can be utilized for drug release. 
Linkers used to conjugate drug should be stable in circulation to support the successful 
delivery of ADC (Lu et al., 2016, Dubowchik and Walker, 1999). 
Previously, ADC incorporated drugs that display clinical activity as free drugs, 
such as methotrexate, vinblastine, and doxorubicin. Generally, these ADCs require 
improvement as high dosage levels are requisite to achieve significant antitumor 
activity. To increase doxorubicin conjugate potency, for example, increasing the 
drug:MAb ratio over a range of 1–25 molecules of drug per one molecule of MAb was 
achieved apart from the use of a branched linker and polymeric carriers (Trail, 2013). 
Currently, most ADC programs undergoing clinical testing incorporate cytotoxic agents 
that are 100–1000-fold more potent. These agents, which previously failed as free drugs 
because of high toxicity and lack of therapeutic index, include calicheamicin, 
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maytansinoids, auristatin, and duocarmycins. Cytotoxic drugs currently being exploited 
to construct ADC fall into two categories that target cell microtubules and DNA 
molecules (Trail, 2013).  
Probably the most advanced drug conjugate (auristatin analogs) is the vc-
MMAE anti-CD30, also called SGN-35. Upon antigen-specific binding and cell 
internalization, the conjugate linker is cleavable by lysosomal enzymes and releases 
active MMAE. MMAE binds to the vinca binding site of tubulin and inhibits tubulin 
polymerization resulting in the GM2/M phase arrest in the cell cycle and ultimately in 
cell death. The drug can kill cells in close proximity even if the cells lack target antigen 
expression because of the membrane permeable properties (Okeley et al., 2010). Among 
CD30+ patients with relapse lymphoma, almost 50% had a reduction in tumor burden in 
the SGN-35 phase 1 trial including 11 complete remissions. The same unconjugated 
anti-CD30 MAb evaluated in a similar population of patients showed minimal efficacy 
(Younes et al., 2010). These data indicate the importance of drug delivery through MAb 
targeting, and incorporating an additional effector mechanism of MAb-mediated drug  
delivery can improve unconjugated MAb activity. Unlike MMAE, the MMAF 
ADC analog is highly impermeable and therefore does not exhibit a significant 
bystander killing activity. However, MMAF may theoretically provide an important 
advantage because of its reduced off-target toxicity.  
Other examples of ADC with microtubule-targeted drugs are DM1 and DM4. 
Generally, the anti-tumor activity of these maytansinoid conjugates correlate with their 
disulfide linker stability. HuC242-SPP-DM1 seems less stable with a shorter half-life 
than hu242-SPDB-DM4, which shows better results in pre-clinical models. The 
bystander killing effects were considered to contribute to the explanation for the 
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improved anti-tumor activity (Kozak and Raab, 2013).  
Chemical compounds that target DNA are also used as payloads for ADCs. 
Calicheamicin from Micromonospora calichensis is one of the most potent DNA 
cleaving agents (Lee et al., 1992). An anti-CD22 calicheamicin conjugate is considered 
the most advanced calicheamicin-based ADC under clinical evaluation for the treatment 
of aggressive and indolent non-Hodgkin lymphoma (Kantarjian et al., 2012). 
1.4.11 Peripheral blood and surface marker proteins 
1.4.11(a) Types of cells present in human peripheral blood mononuclear cells 
The peripheral whole blood contains a mixture of different types of cells largely divided 
into red blood cells, white blood cells, and platelets. To study cells that are involved in 
the immune system, drawn peripheral whole blood is usually processed to isolate white 
blood cells by density gradient centrifugation. This method commonly uses a high-
density polysucrose solution (Fuss et al., 2001). The sucrose polymer separates blood 
cells based on density of below and above 1.007 g/ml. During centrifugation, red blood 
cells are aggregated by polysucrose and rapidly sedimented. Granulocytes become 
slightly hypertonic, thus increasing their sedimentation rate, and pelleting occurs at the 
bottom of the centrifugation tube. Polymorphonuclear cells (PMNs), which include 
neutrophils and eosinophils, are sedimented, and they become denser than 1.007 g/ml. 
Three major fractions are obtained after centrifugation (Fuss et al., 2009). The top 
fraction consists of blood plasma, which has the lowest density; the second fraction is 
the polysucrose solution; and the bottom fraction comprises red blood cells, PMNs, and 
granulocyte sediments. Lymphocytes and other mononuclear cells called PBMC remain 
as a thin layer between the plasma and the polysucrose interface. This layer, which is 
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usually referred to as a buffy coat, is composed of the cells collected when this method 
is used for PBMC isolation (Figure 1.5). These cells comprise of mainly lymphocytes, 
monocytes as well their subtypes including B cell, T cells, NK and more (de Almeida et 
al., 2000). 
 
 
 
 
 
 
 
 
 
Figure 1.5 Flow cytometric analysis of cell population after PBMC  isolation using 
density gradient centrifugation. 
 
1.4.11(b) Peripheral blood CD markers 
Peripheral blood cells express various protein molecules on their cell surface. For each 
cell subtype, unique molecules or proteins are expressed and dedicated specifically to a 
particular subtype (Maecker et al., 2012). During the cell lifetime, different protein 
molecules can be expressed by cells that are associated with the stages of cell 
development. Therefore, these proteins have become signature proteins or markers to a 
specific peripheral blood subtype. Almost 400 protein markers (Zola, 2007) known as 
CD markers can be found on the surface of cells in the human body. All cells have at 
least one CD marker, and these markers are mostly useful in classifying leucocytes. 
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1.4.12 Key lymphocyte CDs 
1.4.12(a) CD3 
In the early development of T cells, CD3 protein is expressed in the cell cytoplasm. At a 
later development stage, the CD3 migrates to the cell membrane. The CD3 is found in 
all mature T cells. Virtually no other cell type expresses CD3 except a small number of 
Purkinje cells (DeJarnette et al., 1998). The consistent expression of CD3 on T cells is 
utilized to distinguish T-cell lymphomas and leukemias from superficially similar B-cell 
and myeloid neoplasm (Dave, 2009).  
1.4.12(b) CD4 
CD4 is a glycoprotein found on the surface of immune cells such as T helper 
cells, monocytes, macrophages, and dendritic cells (Biswas et al., 2003). CD4 is usually 
referred to as a T helper cell because one of its main roles is to send signals to other 
types of immune cells to activate them (Germain, 2002). Initially, two subsets of CD4 T 
cell were identified to comprise Th1 and Th2. To date, at least seven distinct CD4 T-cell 
subsets have been shown to exist, namely, Th1, Th2, Th17, Th9, Th22, Tfh, and iTreg 
cells (Ivanova and Orekhov, 2015). CD4 T cells have the capacity to help B cells make 
antibodies, induce macrophages to develop enhanced microbicidal activity, and recruit 
neutrophils, eosinophils, and basophils to sites of infection and inflammation (Alberts et 
al., 2002). CD4 is the main receptor of the HIV virus binding on lymphocytes, and this 
binding results in a series of conformational changes and eventually the entry of the 
virus into the host cell (Landi et al., 2011). 
1.4.12(c) CD8 
CD8 is a transmembrane glycoprotein that serves as a co-receptor for the T-cell 
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receptor. CD8 is predominantly expressed on the surface of CTL, but it can also be 
found in NK cells, cortical thymocytes, and dendritic cells (Xiao et al., 2007). CTLs are 
activated when they recognize MHC class I proteins altered by infiltrated cells. 
Activated CTLs secrete the essential cytolytic mediators (perforin and granzyme) and 
induce apoptosis in target cells, such as tumor cells or viral infected cells (Ito and 
Seishima, 2010). CD8 expression usually remains in T-cell lymphoblastic 
lymphoma and hypo-pigmented mycosis fungoides infection but is frequently lost in 
other T-cell neoplasms (Carulli et al., 2009). 
1.4.12(d) CD19 
The B-lymphocyte marker, CD19, is specifically expressed on the surface of B cells as 
well as follicular dendritic cells. The surface density of CD19 is highly regulated 
throughout B-cell development (Sato et al., 1997). However B cells lose their protein 
expression during terminal plasma cell differentiation. CD19 expression is highly 
conserved in most B-cell tumors although the level of expression is variable according 
to different subtypes. CD19 levels can potentially be useful as a diagnostic tool in 
distinguishing certain lymphoma subtypes (Wang et al., 2012). 
1.4.12(e) CD56/CD16 
In human peripheral blood, five NK subpopulations can be defined on the basis of the 
relative expressions of the CD16 or FcγRIIIA and CD56 markers (Poli et al., 2009). 
Some NKs may express a comparatively high number of one CD marker than the other, 
and some express may very low and even no expressions at all of one CD marker. These 
expression levels are identified as bright, dim, positive, and negative expressions. For 
instance, the two major subsets are CD56
bright
 CD16
dim/-
 and CD56
dim
 CD16
+
, 
